{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:39:00Z","timestamp":1778535540257,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.rdc.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T01:45:45Z","timestamp":1491443145000},"page":"173-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Contraception in Patients with Rheumatic Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Lisa R.","family":"Sammaritano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.rdc.2016.12.001_bib1","doi-asserted-by":"crossref","first-page":"b2895","DOI":"10.1136\/bmj.b2895","article-title":"Contraception for women: an evidence based overview","volume":"339","author":"Amy","year":"2009","journal-title":"Br Med J"},{"key":"10.1016\/j.rdc.2016.12.001_bib2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1110855","article-title":"Effectiveness of long-acting reversible contraception","volume":"366","author":"Winner","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"60","key":"10.1016\/j.rdc.2016.12.001_bib3","first-page":"1","article-title":"Current contraceptive use in the United States 2006 \u2013 2010, and changes in patterns of use since 1995","author":"Jones","year":"2012","journal-title":"Natl Health Stat Report"},{"key":"10.1016\/j.rdc.2016.12.001_bib4","unstructured":"Available at: http:\/\/www.cdc.gov\/nchs\/fastats\/contraceptive.htm. Accessed August 19, 2016."},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.23712","article-title":"Risk of unintended pregnancy among women with systemic lupus erythematosus","volume":"59","author":"Schwartz","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2016.12.001_bib6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/acr.20402","article-title":"Contraceptive counseling and use among women with systemic lupus: a gap in health care quality?","volume":"63","author":"Yazdany","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib7","first-page":"1266","article-title":"Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease","volume":"34","author":"\u00d8stensen","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/AOG.0000000000000279","article-title":"Receipt of prescription contraception by commercially insured women with chronic medical conditions","volume":"123","author":"DeNoble","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/AOG.0000000000001134","article-title":"Contraceptive use among women with medical conditions in a nationwide privately insured population","volume":"126","author":"Champaloux","year":"2015","journal-title":"Obstetrics Gynecol"},{"issue":"5","key":"10.1016\/j.rdc.2016.12.001_bib10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archpedi.154.5.478","article-title":"Improving rheumatologist\u2019 screening for alcohol and sexual activity","volume":"154","author":"Britto","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"10.1016\/j.rdc.2016.12.001_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0961203315596079","article-title":"Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication","volume":"25","author":"Ferguson","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.rdc.2016.12.001_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2307\/2135759","article-title":"Efficacy of the simultaneous use of condoms and spermicides","volume":"23","author":"Kestelman","year":"1991","journal-title":"Fam Plann Perspect"},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.contraception.2006.12.024","article-title":"Worldwide use of intrauterine devices for contraception","volume":"75","author":"D\u2019Arcangues","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.rdc.2016.12.001_bib14","unstructured":"World Health Organization. Medical eligibility for criteria for contraceptive use. 2015. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/181468\/1\/9789241549158_eng.pdf. Accessed August 19, 2016."},{"issue":"2","key":"10.1016\/j.rdc.2016.12.001_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(01)00302-X","article-title":"Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years","volume":"65","author":"Hidalgo","year":"2002","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.rdc.2016.12.001_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.contraception.2010.01.010","article-title":"Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women","volume":"81","author":"Lyus","year":"2010","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.rdc.2016.12.001_bib17","doi-asserted-by":"crossref","first-page":"144.e1-8","DOI":"10.1016\/j.ajog.2007.03.031","article-title":"A\u00a0randomized trial of the intrauterine device versus hormonal contraception in women who are infected with the human immunodeficiency virus","volume":"197","author":"Stringer","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.rdc.2016.12.001_bib18","series-title":"Comprehensive Gynecology","first-page":"237","article-title":"Family planning","author":"Rivlin","year":"2016"},{"issue":"2","key":"10.1016\/j.rdc.2016.12.001_bib19","doi-asserted-by":"crossref","first-page":"134.e1-6","DOI":"10.1016\/j.ajog.2007.04.027","article-title":"Transdermal hormonal contraception: benefits and risks","volume":"197","author":"Burkman","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.rdc.2016.12.001_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-0037-1616237","article-title":"Risk factors in venous thromboembolism","volume":"86","author":"Martinelli","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rdc.2016.12.001_bib21","doi-asserted-by":"crossref","first-page":"h4847","DOI":"10.1136\/bmj.h4847","article-title":"Contraceptive and hormonal treatment options for women with history of venous thromboembolism","volume":"351","author":"Stam-Slob","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.rdc.2016.12.001_bib22","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thromboembolic risk of oral contraceptives, effects of oestrogen dose and progestin type: results of the MEGA case-control study","volume":"339","author":"Van Hylckama Vlieg","year":"2009","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.rdc.2016.12.001_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2003-38334","article-title":"Venous and arterial thrombosis during oral contraceptive use: risks and risk factors","volume":"3","author":"Tanis","year":"2003","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.rdc.2016.12.001_bib24","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.STR.0000015345.61324.3F","article-title":"Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke","volume":"33","author":"Kemmeren","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.rdc.2016.12.001_bib25","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.12.001_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(97)00118-2","article-title":"The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women","volume":"56","author":"Lewis","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.rdc.2016.12.001_bib27","first-page":"727","article-title":"ACOG Comm Opinion number 415: Depo-medroxyprogesterone acetate and bone effects","volume":"12","author":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.rdc.2016.12.001_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0010-7824(01)00234-7","article-title":"Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis","volume":"64","author":"Hennessy","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.rdc.2016.12.001_bib29","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.12.001_bib30","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1056\/NEJMoa050817","article-title":"A\u00a0trial of contraceptive methods in women with systemic lupus erythematosus","volume":"353","author":"Sanchez-Guerrero","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2016.12.001_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.contraception.2010.08.012","article-title":"Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients","volume":"83","author":"Chabbert-Buffet","year":"2011","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.rdc.2016.12.001_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/ard.55.2.94","article-title":"Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis","volume":"55","author":"Jorgensen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2016.12.001_bib33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.61.5.405","article-title":"Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis","volume":"61","author":"Drossaers-Bakker","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2016.12.001_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.contraception.2010.02.003","article-title":"Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review","volume":"82","author":"Farr","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.rdc.2016.12.001_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.contraception.2006.12.022","article-title":"Contraindications to oral contraceptive use among women in the United States 1999-2001","volume":"75","author":"Shortridge","year":"2007","journal-title":"Contraception"},{"issue":"10","key":"10.1016\/j.rdc.2016.12.001_bib36","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","article-title":"Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study","volume":"73","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2016.12.001_bib37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3899\/jrheum.131345","article-title":"Increased risks of deep vein thrombosis and pulmonary embolism in Sj\u00f6gren syndrome: a nationwide cohort study","volume":"41","author":"Chung","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2016.12.001_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.berh.2012.12.005","article-title":"Thrombosis in vasculitis","volume":"27","author":"Gaffo","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2016.12.001_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib40","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.081194","article-title":"Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus","volume":"36","author":"Danowski","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2016.12.001_bib41","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody\u2013positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2016.12.001_bib42","first-page":"735","article-title":"The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome","volume":"86","author":"Forastiero","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.rdc.2016.12.001_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2003-11-4085","article-title":"The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus","volume":"104","author":"Brouwer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2016.12.001_bib44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00001721-199606000-00011","article-title":"Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies","volume":"7","author":"Girolami","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"11","key":"10.1016\/j.rdc.2016.12.001_bib45","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rdc.2016.12.001_bib46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0961203310383300","article-title":"Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome","volume":"20","author":"Yamakami","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.rdc.2016.12.001_bib47","doi-asserted-by":"crossref","first-page":"e4944","DOI":"10.1136\/bmj.e4944","article-title":"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis","volume":"345","author":"Mantha","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.rdc.2016.12.001_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/GCO.0b013e328355871d","article-title":"Thrombotic risks of oral contraceptives","volume":"24","author":"Rott","year":"2012","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.contraception.2004.07.009","article-title":"Progestogen-only contraception in women at high risk of venous thromboembolism","volume":"70","author":"Conard","year":"2004","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.rdc.2016.12.001_bib50","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.contraception.2011.06.008","article-title":"Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives","volume":"84","author":"Vaillant-Roussel","year":"2011","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.rdc.2016.12.001_bib51","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3324\/haematol.2015.134882","article-title":"Risk of recurrent venous thromboembolism on progestin-only contraception: cohort study","volume":"101","author":"Le Moigne","year":"2016","journal-title":"Haematologica"},{"issue":"RR-4","key":"10.1016\/j.rdc.2016.12.001_bib52","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2010","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.rdc.2016.12.001_bib53","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/00006250-200606000-00055","article-title":"ACOG practice bulletin number 73: use of hormonal contraception in women with coexisting medical conditions","volume":"107","author":"ACOG Committee on Practice Bulletins \u2013 Gynecology","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.rdc.2016.12.001_bib54","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/0961203306071706","article-title":"Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil)","volume":"15","author":"Pisoni","year":"2006","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.rdc.2016.12.001_bib55","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2011-03-345678","article-title":"Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception","volume":"118","author":"van Vlijmen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2016.12.001_bib56","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/0002-9378(90)90556-M","article-title":"Interactions with oral contraceptives","volume":"163","author":"Fotherby","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.rdc.2016.12.001_bib57","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/j.1875-9114.1997.tb03082.x","article-title":"Mycophenolate mofetil","volume":"17","author":"Sievers","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.rdc.2016.12.001_bib58","first-page":"853","article-title":"Drug interactions between oral contraceptives and antibiotics","volume":"98","author":"Dickinson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.rdc.2016.12.001_bib59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.clpt.2003.08.009","article-title":"The interaction between St. John\u2019s wort and an oral contraceptive","volume":"74","author":"Hall","year":"2003","journal-title":"Clin Pharmacol Ther"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X16301041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X16301041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:15:49Z","timestamp":1760181349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X16301041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0889857X16301041"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2016.12.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contraception in Patients with Rheumatic Disease","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}